Welcome to our dedicated page for Forian news (Ticker: FORA), a resource for investors and traders seeking the latest updates and insights on Forian stock.
Forian Inc. (Nasdaq: FORA) stands at the forefront of delivering advanced data science-driven solutions and analytics to the healthcare and life sciences sectors. With a comprehensive suite of Software as a Service (SaaS) tools, data management capabilities, and proprietary analytics, Forian is dedicated to optimizing and measuring operational, clinical, and financial performance. Their offerings cater to a wide range of clients including traditional and emerging life sciences companies, healthcare payers and providers, as well as cannabis dispensaries, manufacturers, and cultivators.
Headquartered in Newtown, PA, Forian has carved a niche in the industry by providing unparalleled insights through their data products. By integrating and normalizing large-scale healthcare data, Forian creates distinctive information assets and proprietary insights, tailored to meet the diverse needs of their clients.
Forian’s recent achievements include a strategic stock repurchase, indicating their robust financial health and confidence in their growth trajectory. Additionally, the company has demonstrated consistent revenue growth and positive Adjusted EBITDA, reflecting its operational efficiency and market positioning.
Forian also emphasizes collaboration and partnerships to enhance its product offerings. Their data management and analytics solutions are designed to support the evolving needs of the healthcare and life sciences industries, driving better decision-making and outcomes.
Stay updated with Forian's latest news and developments as the company continues to innovate and lead in the realm of data-driven healthcare solutions.
Forian Inc. (FORA) reported Q3 2024 financial results showing revenue of $4.7 million, a 12% decrease from $5.3 million in the prior year. The company recorded a net loss of $0.2 million ($0.01 per share), compared to net income of $4.3 million ($0.13 per share) in Q3 2023. Adjusted EBITDA decreased to $0.2 million from $1.1 million year-over-year. Cash and equivalents stood at $49.4 million. Notable events include the acquisition of Kyber Data Science and the redemption of 3.5% Convertible Notes worth over $15 million.
Forian Inc. (Nasdaq: FORA) has announced its participation in the 13th Annual ROTH MKM Technology Event, scheduled for November 19th-20th, 2024, at the Hard Rock Hotel in New York City. CEO and Executive Chairman Max Wygod and CFO Mike Vesey will represent the company at this exclusive event, which will feature over 70 growth companies from the technology sector.
The event format consists of 40-minute one-on-one and small group meetings between company executives and investors, providing opportunities for detailed discussions and comprehensive insights into participating companies.
Forian (Nasdaq: FORA), a provider of data science driven information and analytics solutions to healthcare and life sciences industries, has scheduled its third quarter 2024 financial results announcement for November 13, 2024, after market close. The company will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results. A replay of the call will be available on the company's investor website following the conclusion.
Forian Inc. (Nasdaq: FORA) has acquired Kyber Data Science from TD Cowen, strengthening its position in healthcare information analytics. Kyber specializes in advanced healthcare data analytics and machine learning solutions for the financial services industry. The acquisition expands Forian's market reach into financial services and adds Kyber's proprietary algorithms and software designed for hedge funds, private equity, and mutual fund customers. The merger combines Forian's data resources with Kyber's analytics capabilities to enhance services for both healthcare and financial industry clients.
Forian Inc. (Nasdaq: FORA) reported its Q2 2024 financial results, showing a slight decline in revenue and increased losses. Key points include:
- Revenue decreased 2% to $4.8 million
- Net loss from continuing operations increased to $2.6 million ($0.08 per share)
- Adjusted EBITDA decreased 81% to $0.08 million
- Cash, cash equivalents, and marketable securities totaled $48.0 million
The company expanded its Chronos™ data lake to offset potential data loss from a supplier. Forian updated its 2024 outlook, projecting revenue between $19-20 million and Adjusted EBITDA ranging from -$0.5 million to $0.5 million. Despite industry challenges, Forian remains focused on product differentiation and cost containment.
Forian Inc. (Nasdaq: FORA), a provider of data science driven information and analytics solutions for healthcare and life sciences industries, has announced it will release its second quarter 2024 financial results on Wednesday, August 14, 2024, after market close. The company will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results.
Interested parties can register for the conference call online, and the webcast will be available live at a specified link. The earnings release and a replay of the call will be accessible on Forian's investor relations website promptly after the call concludes.
FAQ
What is the current stock price of Forian (FORA)?
What is the market cap of Forian (FORA)?
What does Forian Inc. specialize in?
Who are Forian's primary customers?
What recent financial achievements has Forian accomplished?
How does Forian provide value to its clients?
Where is Forian Inc. headquartered?
What are some of Forian's latest updates?
How does Forian integrate data for its analytics solutions?
What makes Forian's data products unique?
How can investors stay informed about Forian's updates?
What sectors does Forian's expertise cover?
